In an attempt to bolster its presence in the cell therapy market, Roche has agreed to acquire Poseida Therapeutics for US$1.5 B. Through the takeover, Roche will gain access to Poseida’s cell therapy assets targeting haematologic cancers, autoimmune diseases, and solid tumours as well as its genetic editing platforms. The acquisition strengthens the existing partnership between Roche and Poseida, which was initiated through their collaboration and license agreement in July 2022. The transaction is expected to close by the first quarter of 2025.